Acute Drug-Induced Dystonia

Drug Induced Movement Disorders: Second Edition

Volumn , Issue , 2008, Pages 72-102

  Mazurek, Michael F ^a   Rosebush, Patricia I ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Dystonic reactions; Neurological complications; Oculogyric dystonia; Patients; Tourette's syndrome

Indexed keywords

EID: 84867012334     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470753217.ch5     Document Type: Chapter

References (188)

1. Swett C, Jr. Drug-induced dystonia. Am J Psychiatry 1975; 132: 532-534.
2. Mazurek MF, Rosebush PI. A prospective study of neuroleptic-induced dystonia: incidence and relationship to age, sex, medications and concurrent parkinsonism. Neurology 1991; 41(suppl 1): 274.
3. Mazurek MF, Rosebush PI. Drug-induced dystonia in patients taking neuroleptic medication for the first time. Mov Disord 1992; 7(suppl 1): 54.
4. Mazurek MF, Rosebush PI. Circadian pattern of acute, neuroleptic-induced dystonic reactions. Am J Psychiatry 1996; 153: 708-710.
5. Rosebush PI, Mazurek MF. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology 1999; 52: 782-785.
6. Flaherty JA, Lahmeyer HW. Laryngeal-pharyngeal dystonia as a possible cause of asphyxia with haloperidol treatment. Am J Psychiatry 1978; 135: 1414-1415.
7. Newton-John H. Acute upper airway obstruction due to supraglottic dystonia induced by a neuroleptic. Br Med J 1988; 297: 964-965.
8. Wilson SAK. Epidemic encephalitis. In Bruce AN (ed) Neurology. London, Edward Arnold, 1940, pp. 99-144.
9. Jelliffe SE. Psychologic components in postencephalitic oculogyric crisis. Arch Neurol Psychiatry 1929; 21: 491-532.
10. Owens DGC. A guide to the extrapyramidal side-effects of antipsychotic drugs. Cambridge UK, Cambridge University Press, 1999.
11. Ayd FJ. A survey of drug-induced extrapyramidal reactions. JAMA 1961; 175: 1054-1060.
12. Keepers GA, Clappison VJ, Casey DE. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry 1983; 40: 1113-1117.
13. Singh H, Levinson DF, Simpson GM, et al. Acute dystonia during fixed-dose neuroleptic treatment. J Clin Psychopharmacol 1990; 10: 389-396.
14. McCowan PK, Cook LC. Oculogyric crises in chronic epidemic encephalitis. Brain 1928; 51: 285-309.
15. Remington GJ, Voineskos G, Pollock B, et al. Prevalence of neuroleptic-induced dystonia in mania and schizophrenia. Am J Psychiatry 1990; 147: 1231-1233.
16. Chakos MH, Mayerhoff DI, Loebel AD, et al. Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia. Psychopharmacol Bull 1992; 28: 81-86.
17. Aguilar EJ, Keshavan MS, Martinez-Quiles MD, et al. Predictors of acute dystonia in first-episode psychotic patients. Am J Psychiatry 1994; 151: 1819-1821.
18. Tan CH, Chiang PC, Ng LL, et al. Oculogyric spasm in Asian psychiatric in-patients on maintenance medication. Br J Psychiatry 1994; 165: 381-383.
19. Keepers GA, Casey DE. Prediction of neuroleptic-induced dystonia. J Clin Psychopharmacol 1987; 7: 342-345.
20. Kumor K, Sherer M, Jaffe J. Haloperidol-induced dystonia in cocaine addicts. Lancet 1986; 2(8519): 1341-1342.
21. Choy-Kwong M, Lipton RB. Cocaine withdrawal dystonia. Neurology 1990; 40: 863-864.
22. Hegarty AM, Lipton RB, Merriam AE, et al. Cocaine as a risk factor for acute dystonic reactions. Neurology 1991; 41: 1670-1672.
23. van Harten PN, van Trier JC, Horwitz EH, et al. Cocaine as a risk factor for neuroleptic-induced acute dystonia. J Clin Psychiatry 1998; 59: 128-130.
24. Merab J. Acute dystonic reaction to cocaine. Am J Med 1988; 84: 564.
25. Choy-Kwong M, Lipton RB. Dystonia related to cocaine withdrawal: a case report and pathogenic hypothesis. Neurology 1989; 39: 996-997.
26. Khanna R, Das A, Damodaran SS. Prospective study of neuroleptic-induced dystonia in mania and schizophrenia. Am J Psychiatry 1992; 149: 511-513.
27. National Institute of Mental Health Psychopharmacology and Service Center Collaborative Study Group. Phenothiazine treatment in acute schizophrenia. Arch Gen Psychiatry 1964; 10: 246-261.
28. Cole JD, Davis JM. Antipsychotic Drugs. New York, Grune and Stratton, 1969.
29. Baldessarini RJ, Katz B, Cotton P. Dissimilar dosing with high-potency and low-potency neuroleptics. Am J Psychiatry 1984; 141: 748-752.
30. Snyder S, Greenberg D, Yamamura HI. Antischizophrenic drugs and brain cholinergic receptors: affinity for muscarinic sites predicts extrapyramidal effects. Arch Gen Psychiatry 1974; 31: 58-61.
31. Kieburtz KD, Epstein LG, Gelbard HA, et al. Excitotoxicity and dopaminergic dysfunction in the acquired immunodeficiency syndrome dementia complex: therapeutic implications. Arch Neurol 1991; 48: 1281-1284.
32. Hriso E, Kuhn T, Majdeu JC, et al. Extrapyramidal symptoms due to dopamine blocking agents in patients with AIDS encephalopathy. Am J Psychiatry 1991; 148: 1558-1561.
33. Factor SA, Podskalny GD, Barron KD. Persistent neuroleptic induced rigidity and dystonia in AIDS dementia complex: a clinico-pathological case report. J Neurol Sci 1994; 127: 114-120.
34. Manji H, Sweeney B, Connolly S, et al. Movement disorders in AIDS: infective, neoplastic and iatrogenic causes. Parkinsonism Relat Disord 1995; 1: 13-19.
35. Scamvougeras A, Rosebush PI. AIDS-related psychosis with catatonia responding to low-dose lorazepam. J Clin Psychiatry 1992; 53: 414-415.
36. Factor SA, Troche-Panetto M, Weaver SA. Dystonia in AIDS: Report of four cases. Mov Disord 2003; 18: 1492-1498.
37. Berger JR, Nath A. HIV dementia and the basal ganglia. Intervirology 1997; 40: 122-131.
38. Nath A, Anderson C, Jones M, et al. Neurotoxicity and dysfunction of dopamine systems associated with AIDS dementia. J Clin Psychopharmacol 2000; 14: 222-227.
39. Wiley CA, Soontornniyomkij V, Radhakrishnan L, et al. Distribution of brain HIV load in AIDS. Brain Pathol 1998; 8: 277-284.
40. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-796.
41. Kastrup O, Gastpar M, Schwarz M. Acute dystonia due to clozapine. J Neurol Neurosurg Psychiatry 1994; 57: 119.
42. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13: 25-40.
43. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825-835.
44. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995; 166: 712-726.
45. Abi-Dargham A, Laruelle M, Aghajanian GK, et al. The role of serotonin in the pathophysiology and treatment of schizophrenia. J Neuropsychiatry Clin Neurosci 1997; 9: 1-17.
46. Busatto GF, Pilowsky LS, Ell PJ, et al. Dopamine D2 receptor occupancy in vivo and response to the new antipsychotic risperidone. Br J Psychiatry 1993; 163: 833-834.
47. Leysen JE, Gommeren W, Eens A, et al. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988; 247: 661-670.
48. Rosebush PI, Mazurek MF. The neurological side-effects of risperidone. Essent Psychopharmacol 1999; 3: 43-64.
49. Simpson GM, Lindenmayer JP. Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol 1997; 17: 194-201.
50. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347: 314-321.
51. Sathpathy S, Winsberg B. Extrapyramidal symptoms in children on atypical antipsychotic drugs. J Clin Psychopharmacol 2003; 23: 675-677.
52. Dickson R, Williams R, Dalby D. Dystonic reaction and relapse with clozapine discontinuation and risperidone initiation. Can J Psychiatry 1994; 39: 184.
53. Lombroso PJ, Scorhill L, King RA, et al. Risperidone treatment of children and adolescents with chronic tic disorders. A preliminary report. J Am Acad Child Adolesc Psychiatry 1995; 34: 1147-1152.
54. Radford JM, Brown TM, Borison RL. Unexpected dystonia while changing from clozapine to risperidone. J Clin Psychopharmacol 1995; 15: 225-226.
55. Mandoki MW. Risperidone treatment of children and adolescents: increased risk of ex-trapyramidal side effects? J Child Adolesc Psychopharmcol 1995; 5: 49-67.
56. Anand HS. Re: Acute dystonic reaction with risperidone. Can J Psychiatry 1996; 41: 412.
57. Brody AL. Acute dystonia induced by rapid increase in risperidone dosage. J Clin Psychopharmacol 1996; 16: 461-462.
58. Cheslik TA, Erramouspe J. Extrapyramidal symptoms following accidental ingestion of risperidone in a child. Ann Pharmacother 1996; 30: 360-363.
59. Faulk RS, Gilmore JH, Jensen EW, et al. Risperidone-induced dystonic reaction. Am J Psychiatry 1996; 153: 577.
60. Sanderson DR. Drug interaction between risperidone and phenytoin resulting in ex-trapyramidal symptoms. J Clin Psychiatry 1996; 57: 177.
61. Takhar J, Manchanda R. Acute dystonic reaction with risperidone. Can J Psychiatry 1996; 41: 61-62.
62. Brown ES. Extrapyramidal side effects with low-dose risperidone. Can J Psychiatry 1997; 42: 325-326.
63. Rosebush PI, Mazurek MF. Extrapyramidal side-effects of risperidone. Neurology 1997; 48: 325-326.
64. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14: 87-96.
65. Bymaster F, Perry KW, Nelson DL, et al. Olanzapine: a basic science update. Br J Psychiatry 1999; 174 (suppl 37): 36-40.
66. Tollefson GD, Beasley CM, Jr., Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154: 457-465.
67. Gomez JC, Sacristan JA, Hernandez J, et al. The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). J Clin Psychiatry 2000; 61: 335-343.
68. Wright P, Birkett M, David SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001; 158: 1149-1151.
69. Landry P, Cournoyer J. Acute dystonia with olanzapine. J Clin Psychiatry 1998; 59: 384.
70. Alevizos B, Papageorgiou C, Christodoulou GN. Acute dystonia caused by low dosage of olanzapine. J Neuropsychiatry Clin Neurosci 2003; 15: 241.
71. Hagberg G, Gefvert O, Bergstrom M, et al. N-[11C]methylspiperone PET, in contrast to [11C]raclopride, fails to detect D2 receptor occupancy by an atypical neuroleptic. Psychiatry Res 1998; 82: 147-160.
72. Gefvert O, Bergstrom M, Langstrom B, et al. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology 1998; 135: 119-126.
73. Jonnalagada JR, Norton JW. Acute dystonia with quetiapine. Clin Neuropharmacol 2000; 23: 229-230.
74. Nishikawa T, Nishioka S. A case of Meige dystonia induced by short-term quetiapine treatment. Hum Psychopharmacol Clin Exp 2002; 17: 197.
75. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997; 42: 233-246.
76. Peuskens J, Link CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiat Scand 1997; 96: 265-273.
77. Sallee FR, Kurlan R, Goetz CG, et al. Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 2000; 48: 292-299.
78. Hollander H, Golden J, Mendelson T, et al. Extrapyramidal symptoms in AIDS patients given low-dose metoclopramide or chlorpromazine. Lancet 1985; 2 (8465): 1186.
79. Edelstein H, Knight RT. Severe parkinsonism in two AIDS patients taking prochlorperazine. Lancet 1987; 2 (8554): 341-342.
80. Der Kleij FG, de Vries PA, Stassen PM, et al. Acute dystonia due to metoclopramide: increased risk in AIDS. Arch Int Med 2002; 162: 358-359.
81. Bateman DN, Rawlins MD, Simpson JM. Extrapyramidal reactions with metoclopramide. Br Med J Clin Res Ed 1985; 291: 930-932.
82. Lee HK. Dystonic reactions to amitriptyline and doxepin. Am J Psychiatry 1988; 145: 649.
83. Finder E, Lin KM, Ananth J. Dystonic reaction to amitriptyline. Am J Psychiatry 1982; 139: 1220.
84. Ornadel D, Barnes EA, Dick DJ. Acute dystonia due to amitriptyline. J Neurol Neurosurg Psychiatry 1992; 55: 414.
85. Pande AC, Max P. A dystonic reaction occurring during treatment with tranylcypromine. J Clin Psychopharmacol 1989; 9: 229-230.
86. Meltzer HY, Young M, Metz J, et al. Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transm 1979; 45: 165-175.
87. Leo RJ. Clinical manifestations of dystonia and dyskinesia after SSRI administration. J Clin Psychiatry 1997; 58: 403-404.
88. Shihabuddin L, Rapport D. Sertraline and extrapyramidal side effects. Am J Psychiatry 1994; 151: 288.
89. Coulter DM, Pillans PI. Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1995; 152: 122-125.
90. Reccoppa L, Welch WA, Ware MR. Acute dystonia and fluoxetine. J Clin Psychiatry 1990; 51: 487.
91. George MS, Trimble MR. Dystonic reaction associated with fluvoxamine. J Clin Psychopharmacol 1993; 13: 220-221.
92. Berk M. Paroxetine induces dystonia and parkinsonism in obsessive compulsive disorder. Hum Psychopharmacol Clin Exp 1993; 8: 444-445.
93. Brod TM. Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1989; 146: 13521353.
94. Dave M. Fluoxetine-associated dystonia. Am J Psychiatry 1994; 151: 149.
95. Horrigan JP, Barnhill LJ. Paroxetine-pimozide drug interaction. J Am Acad Child Adolesc Psychiatry 1994; 33: 1060-1061.
96. Gill HS, DeVane CL, Risch SC. Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses. J Clin Psychopharmacol 1997; 17: 377-389.
97. Ketai R. Interaction between fluoxetine and neuroleptics. Am J Psychiatry 1993; 150: 836-837.
98. Metz A. Interaction between fluoxetine and buspirone. Can J Psychiatry 1990; 35: 722-723.
99. Stanislav SW, Childs NL. Dystonia associated with sertraline. J Clin Psychopharmacol 1999; 19: 98-100.
100. Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996; 57: 449-454.
101. Gerber PE, Lynd LD. Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother 1998; 32: 692-698.
102. Wells BG, Hayes PE. Depressive illness. In DiPiro JT, Talbert RL, Hayes PE, et al. (eds) Pharmacotherapy: A Pathophysiologic Approach. New York, Elsevier, 1989, pp. 748-764.
103. Porro V, Fiorenzoni S, Menga C, et al. Single-blind comparison of the efficacy of fluvox-amine versus placebo in patients with depressive syndrome. Curr Ther Res 1988; 43: 621-629.
104. Chuang C, Fahn S, Frucht SJ. The natural history and treatment of acquired hemidysto-nia: report of 33 cases and review of the literature. J Neurol Neurosurg Psychiatry 2002; 72: 59-67.
105. Dauer WT, Burke RE, Greene P, et al. Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia. Brain 1998; 121: 547-560.
106. Tamburin S, Manganotti P, Marzi CA, et al. Abnormal somatotopic arrangement of sensorimotor interactions in dystonic patients. Brain 2002; 125: 12-30.
107. Gerfen CR, Young WS, III. Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: an in situ hybridization histochemistry and fluorescent retrograde tracing study. Brain Res 1988; 460: 161-167.
108. Bolam JP, Smith Y. The GABA and substance P input to dopaminergic neurones in the substantia nigra of the rat. Brain Res 1990; 529(1-2): 57-78.
109. Parent A, Charara A, Pinault D. Single striatofugal axons arborizing in both pallidal segments and in the substantia nigra in primates. Brain Res 1995; 698: 280-284.
110. Parent A, Cicchetti F, Beach TG. Striatal neurones displaying substance P (NK1) receptor immunoreactivity in human and non-human primates. Neuroreport 1995; 6721-6724.
111. Gerfen CR, Engber TM, Mahan LC, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990; 250: 1429-1432.
112. Parent A, Cote PY, Lavoie B. Chemical anatomy of primate basal ganglia. Progr Neuro-biol 1995; 46: 131-197.
113. Calabresi P, Centonze D, Gubellini P, et al. Acetylcholine-mediated modulation of striatal function. Trends Neurosci 2000; 23: 120-126.
114. Kowall NW, Ferrante RJ, Beal MF, et al. Neuropeptide Y, somatostatin, and reduced nicotinamide adenine dinucleotide phosphate diaphorase in the human striatum: a combined immunocytochemical and enzyme histochemical study. Neuroscience 1987; 20: 817-828.
115. Garside S, Woulfe J, Mazurek MF. The ontogeny of NADPH-diaphorase neurons in serum-free striatal cultures parallels in vivo development. Neuroscience 1997; 78: 615-624.
116. Cowan RL, Wilson CJ, Emson PC, et al. Parvalbumin-containing GABAergic interneurons in the rat neostriatum. J Comp Neurol 1990; 302: 197-205.
117. Prensa L, Gimenez-Amaya JM, Parent A. Morphological features of neurons containing calcium-binding proteins in the human striatum. J Comp Neurol 1998; 390: 552-563.
118. Kubota Y, Kawaguchi Y. Dependence of GABAergic synaptic areas on the interneuron type and target size. J Neurosci 2000; 20: 375-386.
119. Fuller TA, Russchen FT, Price JL. Sources of presumptive glutamergic/aspartergic affer-ents to the rat ventral striatopallidal region. J Comp Neurol 1987; 258: 317-338.
120. Dube L, Smith AD, Bolam JP. Identification of synaptic terminals of thalamic or cortical origin in contact with distinct medium-size spiny neurons in the rat neostriatum. J Comp Neurol 1988; 267: 455-471.
121. McGeorge AJ, Faull RL. The organization of the projection from the cerebral cortex to the striatum in the rat. Neuroscience 1989; 29: 503-537.
122. Smith AD, Bolam JP. The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurosci 1990; 13: 259-265.
123. Soghomonian JJ, Descarries L, Watkins KC. Serotonin innervation in adult rat neostriatum. II. Ultrastructural features: a radioautographic and immunocytochemical study. Brain Res 1989; 481: 67-86.
124. McDonald AJ. Topographical organization of amygdaloid projections to the caudatop-utamen, nucleus accumbens, and related striatal-like areas of the rat brain. Neuroscience 1991; 44: 15-33.
125. Takagi H, Somogyi P, Somogyi J, et al. Fine structural studies on a type of somatostatin-immunoreactive neuron and its synaptic connections in the rat neostriatum: a correlated light and electron microscopic study. J Comp Neurol 1983; 214: 1-16.
126. Pickel VM, Chan J. Spiny neurons lacking choline acetyltransferase immunoreactiv-ity are major targets of cholinergic and catecholaminergic terminals in rat striatum. J Neurosci Res 1990; 25: 263-280.
127. Smith Y, Bevan MD, Shink E, et al. Microcircuitry of the direct and indirect pathways of the basal ganglia. Neuroscience 1998; 86: 353-387.
128. Farde L, Nordstrom AL, Wiesel FA, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49: 538-544.
129. Freund TF, Powell JF, Smith AD. Tyrosine hydroxylase-immunoreactive boutons in synaptic contact with identified striatonigral neurons, with particular reference to dendritic spines. Neuroscience 1984; 13: 1189-1215.
130. Parent A, Hazrati LN. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Rev 1995; 20: 91-127.
131. Halpain S, Girault JA, Greengard P. Activation of NMDA receptors induces dephosphorylation of DARPP-32 in rat striatal slices. Nature 1990; 343: 369-372.
132. Cepeda C, Buchwald NA, Levine MS. Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc Natl Acad Sci USA 1993; 90: 9576-9580.
133. Garside S, Furtado JC, Mazurek MF. Dopamine-glutamate interactions in the striatum: behaviourally relevant modification of excitotoxicity by dopamine receptor-mediated mechanisms. Neuroscience 1996; 75: 1065-1074.
134. Lester J, Fink S, Aronin N, et al. Colocalization of D1 and D2 dopamine receptor mRNAs in striatal neurons. Brain Res 1993; 621: 106-110.
135. Surmeier DJ, Song WJ, Yan Z. Coordinated expression of dopamine receptors in neos-triatal medium spiny neurons. J Neurosci 1996; 16: 6579-6591.
136. Aizman O, Brismar H, Uhlen P, et al. Anatomical and physiological evidence for D1 and D2 dopamine receptor colocalization in neostriatal neurons. Nat Neurosci 2000; 3: 226-230.
137. Di Chiara G, Morelli M, Consolo S. Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions. Trends Neurosci 1994; 17: 228-233.
138. Aosaki T, Tsubokawa H, Ishida A, et al. Responses of tonically active neurons in the primate's striatum undergo systematic changes during behavioral sensorimotor conditioning. J Neurosci 1994; 14: 3969-3984.
139. Graybiel AM, Aosaki T, Flaherty AW, et al. The basal ganglia and adaptive motor control. Science 1994; 265: 1826-1831.
140. Blazquez PM, Fujii N, Kojima J, et al. A network representation of response probability in the striatum. Neuron 2002; 33: 973-982.
141. 123I]iodobenzovesamicol binding in idiopathic cervical dystonia. Ann Neurol 2003; 53: 528-532.
142. Aubry JM, Schulz MF, Pagliusi S, et al. Coexpression of dopamine D2 and substance P (neurokinin-1) receptor messenger RNAs by a subpopulation of cholinergic neurons in the rat striatum. Neuroscience 1993; 53: 417-424.
143. Chang HT. Dopamine-acetylcholine interaction in the rat striatum: a dual-labeling im-munocytochemical study. Brain Res Bull 1988; 21: 295-304.
144. Abercrombie ED, DeBoer P. Substantia nigra D1 receptors and stimulation of striatal cholinergic interneurons by dopamine: a proposed circuit mechanism. J Neurosci 1997; 17: 8498-8505.
145. Kawaguchi Y, Wilson CJ, Augood SJ, et al. Striatal interneurones: chemical, physiological and morphological characterization. Trends Neurosci 1995; 18: 527-535.
146. Koos T, Tepper JM. Inhibitory control of neostriatal projection neurons by GABAergic interneurons. Nat Neurosci 1999; 2: 467-472.
147. Martina M, Vida I, Jonas P. Distal initiation and active propagation of action potentials in interneuron dendrites. Science 2000; 287: 295-300.
148. Gernert M, Hamann M, Bennay M, et al. Deficit of striatal parvalbumin-reactive GABAer-gic interneurons and decreased basal ganglia output in a genetic rodent model of idiopathic paroxysmal dystonia. J Neurosci 2000; 20: 7052-7058.
149. Girault JA, Spampinato U, Glowinski J, et al. In vivo release of [3H]gamma-aminobutyric acid in the rat neostriatum-II. Opposing effects of D1 and D2 dopamine receptor stimulation in the dorsal caudate putamen. Neuroscience 1986; 19: 1109-1117.
150. Harsing LG, Jr., Zigmond MJ. Influence of dopamine on GABA release in striatum: evidence for D1-D2 interactions and non-synaptic influences. Neuroscience 1997; 77: 419-429.
151. Delgado A, Sierra A, Querejeta E, et al. Inhibitory control of the GABAergic transmission in the rat neostriatum by D2 dopamine receptors. Neuroscience 2000; 95: 1043-1048.
152. Beal MF, Mazurek MF, Ellison DW, et al. Somatostatin and neuropeptide Y concentrations in pathologically graded cases of Huntington's disease. Ann Neurol 1988; 23: 562-569.
153. Moser A, Cramer H. Somatostatin acts through G-proteins on dopaminergic adenylate cyclase in the caudate-putamen of the rat. Neurochem Res 1990; 15: 1085-1087.
154. Thermos K, Radke J, Kastellakis A, et al. Dopamine-somatostatin interactions in the rat striatum: an in vivo microdialysis study. Synapse 1996; 22: 209-216.
155. Hathway GJ, Emson PC, Humphrey PP, et al. Somatostatin potently stimulates in vivo striatal dopamine and gamma-aminobutyric acid release by a glutamate-dependent action. J Neurochem 1998; 70: 1740-1749.
156. Hathway GJ, Humphrey PP, Kendrick KM. Evidence that somatostatin sst2 receptors mediate striatal dopamine release. Br J Pharmacol 1999; 128: 1346-1352.
157. Le Moine C, Normand E, Bloch B. Phenotypical characterization of the rat striatal neurons expressing the D1 dopamine receptor gene. Proc Natl Acad Sci USA 1991; 88: 4205-4209.
158. MacLennan AJ, Lee N, Vincent SR, et al. D2 dopamine receptor mRNA distribution in cholinergic and somatostatinergic cells of the rat caudate-putamen and nucleus accum-bens. Neurosci Lett 1994; 180: 214-218.
159. Engber TM, Boldry RC, Kuo S, et al. Dopaminergic modulation of striatal neuropeptides: differential effects of D1 and D2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin. Brain Res 1992; 581: 261-268.
160. Izquierdo-Claros RM, Boyano-Adanez MC, Larsson C, et al. Acute effects of D1-and D2-receptor agonist and antagonist drugs on somatostatin binding, inhibition of adenylyl cyclase activity and accumulation of inositol 1,4,5-trisphosphate in the rat striatum. Mol Brain Res 1997; 47: 99-107.
161. Flores-Hernandez J, Galarraga E, Bargas J. Dopamine selects glutamatergic inputs to neostriatal neurons. Synapse 1997; 25: 185-195.
162. Mazurek MF, Savedia SM, Bobba RS, et al. Persistent loss of tyrosine hydroxylase im-munoreactivity in the substantia nigra after neuroleptic withdrawal. J Neurol Neurosurg Psychiatry 1998; 64: 799-801.
163. Levinson AJ, Garside S, Rosebush PI, et al. Haloperidol induces persistent down-regulation of tyrosine hydroxylase immunoreactivity in substantia nigra but not ventral tegmental area in the rat. Neuroscience 1998; 84: 201-211.
164. Mazurek MF, Krasnik C, Rosebush PI, et al. Evidence that antipsychotic drugs and 3-nitroproprionic acid independently induce cell death in mid-brain dopamine neurons by activation of the apoptosis cascade. Ann Neurol 2002; 52: S85-S86.
165. Xu Y, Krasnik C, Bell V, et al. Differential effects of typical vs. atypical antipsychotic drugs on midbrain dopamine neurons. Neurosci Abst 2003; 948-7.
166. Mazurek MF, Krasnik C, Xu Y, et al. Rapid induction of pro-apoptotic proteins in nigral dopamine neurons by antipsychotic medication. Ann Neurol 2003; 54 (suppl 7): S42.
167. Harrison SJ, Mazurek MF. Comparative effects of antipsychotic and antidepressant drugs on dopaminergic, noradrenergic and serotonergic cell groups in the rat. Neurosci Abst 1998; 24: 2179.
168. Lavoie B, Parent A. Immunohistochemical study of the serotoninergic innervation of the basal ganglia in the squirrel monkey. J Comp Neurol 1990; 299: 1-16.
169. Snyder AM, Zigmond MJ, Lund RD. Sprouting of serotoninergic afferents into striatum after dopamine-depleting lesions in infant rats: a retrograde transport and immunocy-tochemical study. J Comp Neurol 1986; 245: 274-281.
170. De Simoni MG, Dal Toso G, Fodritto F, et al. Modulation of striatal dopamine metabolism by the activity of dorsal raphe serotonergic afferences. Brain Res 1987; 411: 81-88.
171. Jackson D, Bruno JP, Stachowiak MK, et al. Inhibition of striatal acetylcholine release by serotonin and dopamine after the intracerebral administration of 6-hydroxydopamine to neonatal rats. Brain Res 1988; 457: 267-273.
172. Middlemiss DN, Bremer ME, Smith SM. A pharmacological analysis of the 5-HT receptor mediating inhibition of 5-HT release in the guinea-pig frontal cortex. Eur J Pharmacol 1988; 157: 101-107.
173. 1b recognition sites. Brain Res 1986; 376: 85-96.
174. 1D in the rabbit and guinea-pig brain cortex. Naunyn-Schmiedebergs Arch Pharmacol 1991; 343: 353-364.
175. 1a autoreceptors modulate 5-HT release in the guinea-pig dorsal raphe nucleus. Neuropharmacology 1994; 33: 393-402.
176. Boschert U, Amara DA, Segu L, et al. The mouse 5-hydroxytryptamine1B receptor is localized predominantly on axon terminals. Neuroscience 1994; 58: 167-182.
177. 1b and 5-HT2C receptors, on GABA-mediated synaptic input to rat substantia nigra pars reticulata neurons in vitro. J Neurosci 1996; 16: 7566-7573.
178. Gellman RL, Aghajanian GK. Serotonin2 receptor-mediated excitation of interneurons in piriform cortex: antagonism by atypical antipsychotic drugs. Neuroscience 1994; 58: 515-525.
179. Pazos A, Palacios JM. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res 1985; 346: 205-230.
180. Ward RP, Dorsa DM. Colocalization of serotonin receptor subtypes 5-HT2a, 5-HT2c, and 5-HT6 with neuropeptides in rat striatum. J Comp Neurol 1996; 370: 405-414.
181. Maricq AV, Peterson AS, Brake AJ, et al. Primary structure and functional expression of the 5HT3 receptor, a serotonin-gated ion channel. Science 1991; 254: 432-437.
182. Davies PA, Pistis M, Hanna MC, et al. The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature 1999; 397: 359-363.
183. Waeber C, Dixon K, Hoyer D, et al. Localisation by autoradiography of neuronal 5-HT3 receptors in the mouse CNS. Eur J Pharmacol 1988; 151: 351-352.
184. Waeber C, Sebben M, Nieoullon A, et al. Regional distribution and ontogeny of 5-HT4 binding sites in rodent brain. Neuropharmacology 1994; 33: 527-541.
185. Monsma FJ, Jr., Shen Y, Ward RP, et al. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol 1993; 43: 320-327.
186. Heidmann DE, Szot P, Kohen R, et al. Function and distribution of three rat 5-hydroxytryptamine7 (5-HT7) receptor isoforms produced by alternative splicing. Neuropharmacology 1998; 37: 1621-1632.
187. Rosebush PI, Mazurek MF. Do benzodiazepines modify the incidence of neuroleptic-induced dystonia? Am J Psychiatry 1993; 150: 528.
188. World Health Organization. Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment: a consensus statement. Br J Psychiatry 1990; 156: 412.